{"transactions":[{"id":2729684,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139745,"kind":"organization","name":"Arkin Bio Ventures 2 L.P.","position":1,"cik":"0001858705","reported_name":"Arkin Bio Ventures 2 L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139746,"kind":"organization","name":"Arkin Bio Ventures GPGP Ltd.","position":2,"cik":"0001858707","reported_name":"Arkin Bio Ventures GPGP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-05-04T20:31:02.000Z","date":"2021-05-04","kind":"exercise","acquired":false,"shares":3560551,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures 2 L.P. (the \"Fund\"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":410717},"source":{"system":"sec-edgar","filing":"0000899243-21-018121","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1321178/000089924321018121/doc4.xml","form_type":"4"}},{"id":2729683,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139745,"kind":"organization","name":"Arkin Bio Ventures 2 L.P.","position":1,"cik":"0001858705","reported_name":"Arkin Bio Ventures 2 L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139746,"kind":"organization","name":"Arkin Bio Ventures GPGP Ltd.","position":2,"cik":"0001858707","reported_name":"Arkin Bio Ventures GPGP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-05-04T20:31:02.000Z","date":"2021-05-04","kind":"exercise","acquired":false,"shares":10714284,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures 2 L.P. (the \"Fund\"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1235917},"source":{"system":"sec-edgar","filing":"0000899243-21-018121","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1321178/000089924321018121/doc4.xml","form_type":"4"}},{"id":2729682,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139745,"kind":"organization","name":"Arkin Bio Ventures 2 L.P.","position":1,"cik":"0001858705","reported_name":"Arkin Bio Ventures 2 L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139746,"kind":"organization","name":"Arkin Bio Ventures GPGP Ltd.","position":2,"cik":"0001858707","reported_name":"Arkin Bio Ventures GPGP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T20:31:02.000Z","date":"2021-05-04","kind":"purchase","acquired":true,"shares":400000,"price":16,"value":6400000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures 2 L.P. (the \"Fund\"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund."}],"balance_after":2046634,"source":{"system":"sec-edgar","filing":"0000899243-21-018121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1321178/000089924321018121/doc4.xml","form_type":"4"}},{"id":2729681,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139745,"kind":"organization","name":"Arkin Bio Ventures 2 L.P.","position":1,"cik":"0001858705","reported_name":"Arkin Bio Ventures 2 L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139746,"kind":"organization","name":"Arkin Bio Ventures GPGP Ltd.","position":2,"cik":"0001858707","reported_name":"Arkin Bio Ventures GPGP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T20:31:02.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":410717,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures 2 L.P. (the \"Fund\"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund."}],"balance_after":1646634,"source":{"system":"sec-edgar","filing":"0000899243-21-018121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1321178/000089924321018121/doc4.xml","form_type":"4"}},{"id":2729680,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139745,"kind":"organization","name":"Arkin Bio Ventures 2 L.P.","position":1,"cik":"0001858705","reported_name":"Arkin Bio Ventures 2 L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139746,"kind":"organization","name":"Arkin Bio Ventures GPGP Ltd.","position":2,"cik":"0001858707","reported_name":"Arkin Bio Ventures GPGP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T20:31:02.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":1235917,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures 2 L.P. (the \"Fund\"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund."}],"balance_after":1235917,"source":{"system":"sec-edgar","filing":"0000899243-21-018121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1321178/000089924321018121/doc4.xml","form_type":"4"}}]}